Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Inflammatory Breast Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Cyclophosphamide 38Paclitaxel 22Epirubicin 21Trastuzumab 20Docetaxel 20Doxorubicin 19Carboplatin 15Radiotherapy 13Taxes 11Filgrastim 11Neoadjuvant Therapy 9Bevacizumab 9Fluorouracil 8pembrolizumab 7Tamoxifen 7Albumin-Bound Paclitaxel 7Capecitabine 6pertuzumab 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Lapatinib 5130-nm albumin-bound paclitaxel 5pegfilgrastim 4Granulocyte Colony-Stimulating Factor 4Cisplatin 4Chemotherapy, Adjuvant 4tipifarnib 3eribulin 3Surgical Procedures, Operative 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Inflammatory Breast Neoplasms × CMF regimen × Clear all
NCT00003680 2013-11-06

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
300 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡